Oncology Medical News about Flebogammadif

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura
Transfusion Medicine, 09/14/09

Julia A et al. – Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count and bleeding, whose incidence is approximately 6·2 for each 100 000 adults per year. In this study, the efficacy and safety of Flebogammadif, a new high–purity IVIG, were assessed by an open, multicentre, non–controlled, prospective study in adult patients with chronic ITP. Flebogammadif was well tolerated and succeeded in providing a haemostatic platelet count in patients with ITP.

<< Previous
Common community acquired infections and subsequent risk of...

Next >>
Platelet-specific alloantigens and antibodies in Tunisian women...